Dr. Agarwal on Second-Line Therapy Selection in Metastatic RCC

Video

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma (mRCC).

If a patient with mRCC has progressed on a VEGF TKI or immunotherapy, physicians should opt for the most effective second-line or salvage therapy. Many of the therapies that are approved in the second-line setting are also approved for later lines of therapy, notes Agarwal. However, the optimal agent in the second-line setting is cabozantinib (Cabometyx), he adds.

Cabozantinib inhibits VEGFR, MET, and AXL kinases. As a monotherapy, cabozantinib is associated with the longest progression-free survival (PFS) in the second-line or third-line setting. The length of PFS is an important factor to consider, explains Agarwal. The longer PFS a patient has, the greater the likelihood that they will live and potentially see subsequent lines of therapy, he concludes.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.